- Home
- ATHE
as 12-20-2024 4:00pm EST
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
| Founded: | 1997 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 10.1M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 121.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $3.19 | Next Earning Date: | 02-15-2025 |
| Revenue: | $2,681,669 | Revenue Growth: | 2.63% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Alterity Therapeutics Limited News
ATHE Breaking Stock News: Dive into ATHE Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
GlobeNewswire
a month ago
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
GlobeNewswire
a month ago
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
GlobeNewswire
2 months ago
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
GlobeNewswire
2 months ago
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
GlobeNewswire
2 months ago
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
GlobeNewswire
2 months ago
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
GlobeNewswire
3 months ago
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
Compare ATHE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATHE Alterity Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.